Logo image of CCCC

C4 THERAPEUTICS INC (CCCC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CCCC - US12529R1077 - Common Stock

2.635 USD
-0.18 (-6.23%)
Last: 12/4/2025, 10:39:04 AM
Fundamental Rating

3

CCCC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While CCCC has a great health rating, there are worries on its profitability. CCCC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CCCC had negative earnings in the past year.
CCCC had a negative operating cash flow in the past year.
In the past 5 years CCCC always reported negative net income.
In the past 5 years CCCC always reported negative operating cash flow.
CCCC Yearly Net Income VS EBIT VS OCF VS FCFCCCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -44.85%, CCCC is in line with its industry, outperforming 54.87% of the companies in the same industry.
CCCC has a Return On Equity (-77.12%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -44.85%
ROE -77.12%
ROIC N/A
ROA(3y)-31.69%
ROA(5y)-25.64%
ROE(3y)-48.97%
ROE(5y)-38.41%
ROIC(3y)N/A
ROIC(5y)N/A
CCCC Yearly ROA, ROE, ROICCCCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

CCCC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CCCC Yearly Profit, Operating, Gross MarginsCCCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

More info and screens

7

2. Health

2.1 Basic Checks

CCCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CCCC has more shares outstanding
Compared to 5 years ago, CCCC has more shares outstanding
There is no outstanding debt for CCCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CCCC Yearly Shares OutstandingCCCC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CCCC Yearly Total Debt VS Total AssetsCCCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

CCCC has an Altman-Z score of -2.91. This is a bad value and indicates that CCCC is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CCCC (-2.91) is comparable to the rest of the industry.
There is no outstanding debt for CCCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.91
ROIC/WACCN/A
WACC8.73%
CCCC Yearly LT Debt VS Equity VS FCFCCCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 5.76 indicates that CCCC has no problem at all paying its short term obligations.
CCCC has a Current ratio of 5.76. This is in the better half of the industry: CCCC outperforms 60.49% of its industry peers.
A Quick Ratio of 5.76 indicates that CCCC has no problem at all paying its short term obligations.
CCCC has a better Quick ratio (5.76) than 62.17% of its industry peers.
Industry RankSector Rank
Current Ratio 5.76
Quick Ratio 5.76
CCCC Yearly Current Assets VS Current LiabilitesCCCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

CCCC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.91%.
CCCC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -10.57%.
CCCC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.73% yearly.
EPS 1Y (TTM)2.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.71%
Revenue 1Y (TTM)-10.57%
Revenue growth 3Y-8.06%
Revenue growth 5Y10.73%
Sales Q2Q%-26.9%

3.2 Future

Based on estimates for the next years, CCCC will show a very strong growth in Earnings Per Share. The EPS will grow by 42.93% on average per year.
Based on estimates for the next years, CCCC will show a very strong growth in Revenue. The Revenue will grow by 103.73% on average per year.
EPS Next Y-4.99%
EPS Next 2Y-5.12%
EPS Next 3Y0.57%
EPS Next 5Y42.93%
Revenue Next Year-21.4%
Revenue Next 2Y-19.86%
Revenue Next 3Y-13.72%
Revenue Next 5Y103.73%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CCCC Yearly Revenue VS EstimatesCCCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
CCCC Yearly EPS VS EstimatesCCCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CCCC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CCCC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CCCC Price Earnings VS Forward Price EarningsCCCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CCCC Per share dataCCCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.12%
EPS Next 3Y0.57%

More info and screens

0

5. Dividend

5.1 Amount

CCCC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

C4 THERAPEUTICS INC

NASDAQ:CCCC (12/4/2025, 10:39:04 AM)

2.635

-0.18 (-6.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-01 2025-10-01/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners67.33%
Inst Owner Change-4%
Ins Owners2.27%
Ins Owner Change2.22%
Market Cap255.36M
Revenue(TTM)30.11M
Net Income(TTM)-119.08M
Analysts86.15
Price Target12.09 (358.82%)
Short Float %5.74%
Short Ratio2.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.34%
Min EPS beat(2)-6.21%
Max EPS beat(2)5.54%
EPS beat(4)2
Avg EPS beat(4)4.54%
Min EPS beat(4)-6.21%
Max EPS beat(4)19.39%
EPS beat(8)4
Avg EPS beat(8)5.54%
EPS beat(12)6
Avg EPS beat(12)5.68%
EPS beat(16)9
Avg EPS beat(16)8.22%
Revenue beat(2)1
Avg Revenue beat(2)36.02%
Min Revenue beat(2)-3.26%
Max Revenue beat(2)75.3%
Revenue beat(4)2
Avg Revenue beat(4)32.63%
Min Revenue beat(4)-3.26%
Max Revenue beat(4)75.3%
Revenue beat(8)5
Avg Revenue beat(8)55.13%
Revenue beat(12)6
Avg Revenue beat(12)31.97%
Revenue beat(16)8
Avg Revenue beat(16)37.82%
PT rev (1m)-1.19%
PT rev (3m)-24.96%
EPS NQ rev (1m)19.46%
EPS NQ rev (3m)35.93%
EPS NY rev (1m)-0.18%
EPS NY rev (3m)0.21%
Revenue NQ rev (1m)-0.32%
Revenue NQ rev (3m)1.32%
Revenue NY rev (1m)4.1%
Revenue NY rev (3m)11.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.48
P/FCF N/A
P/OCF N/A
P/B 1.65
P/tB 1.65
EV/EBITDA N/A
EPS(TTM)-1.67
EYN/A
EPS(NY)-1.67
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS0.31
BVpS1.59
TBVpS1.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.85%
ROE -77.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.69%
ROA(5y)-25.64%
ROE(3y)-48.97%
ROE(5y)-38.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.44%
Cap/Sales 1.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.76
Quick Ratio 5.76
Altman-Z -2.91
F-Score3
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)142.71%
Cap/Depr(5y)110.83%
Cap/Sales(3y)8.81%
Cap/Sales(5y)6.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.71%
EPS Next Y-4.99%
EPS Next 2Y-5.12%
EPS Next 3Y0.57%
EPS Next 5Y42.93%
Revenue 1Y (TTM)-10.57%
Revenue growth 3Y-8.06%
Revenue growth 5Y10.73%
Sales Q2Q%-26.9%
Revenue Next Year-21.4%
Revenue Next 2Y-19.86%
Revenue Next 3Y-13.72%
Revenue Next 5Y103.73%
EBIT growth 1Y-1.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.41%
EBIT Next 3Y-7.58%
EBIT Next 5YN/A
FCF growth 1Y17.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.61%
OCF growth 3YN/A
OCF growth 5YN/A

C4 THERAPEUTICS INC / CCCC FAQ

What is the ChartMill fundamental rating of C4 THERAPEUTICS INC (CCCC) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CCCC.


What is the valuation status for CCCC stock?

ChartMill assigns a valuation rating of 0 / 10 to C4 THERAPEUTICS INC (CCCC). This can be considered as Overvalued.


Can you provide the profitability details for C4 THERAPEUTICS INC?

C4 THERAPEUTICS INC (CCCC) has a profitability rating of 1 / 10.


Can you provide the financial health for CCCC stock?

The financial health rating of C4 THERAPEUTICS INC (CCCC) is 7 / 10.